Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model

Biochemical and Biophysical Research Communications

Volumn 317, Issue 2, 2004, Pages 508-514

  Hashiya, Naotaka ^a   Aoki, Motokuni ^a   Tachibana, Katsuro ^b   Taniyama, Yoshiaki ^a   Yamasaki, Keita ^a   Hiraoka, Kazuya ^a   Makino, Hirofumi ^a   Yasufumi, Kaneda ^a   Ogihara, Toshio ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Blood vessel; Decoy; E2F; Echo contrast microbubble agent; Optison; Restenosis; Ultrasound

Indexed keywords

FS 069; OLIGODEOXYNUCLEOTIDE DERIVATIVE; TRANSCRIPTION FACTOR E2F;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL; CAROTID ARTERY; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; INFLAMMATION; INTIMA; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RAT; REGULATOR GENE; STAINING; TOXICITY; TRANSACTIVATION; ULTRASOUND;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CAROTID ARTERIES; CELL CYCLE PROTEINS; CORONARY RESTENOSIS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; FEASIBILITY STUDIES; GENE THERAPY; MALE; MICROBUBBLES; OLIGODEOXYRIBONUCLEOTIDES; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS; TRANSFECTION; TREATMENT OUTCOME; ULTRASONIC THERAPY;

EID: 11144356848     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.03.070     Document Type: Article

References (28)

1. Gibbons G.H., Dzau V.J. The emerging concept of vascular remodeling. N. Engl. J. Med. 330:1994;1431-1438.
2. Weintraub S.J., Prater C.A., Dean D.C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature. 358:1992;259-261.
3. Pagano M., Draetta G., Durr J. Association of cdk 2 kinase with the transcription factor E2F during S phase. Science. 255:1992;1144-1147.
4. Morishita R., Higaki J., Tomita N., Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ. Res. 82:1998;1023-1028.
5. Mann M.J., Dzau V.J. Therapeutic applications of transcription factor decoy oligonucleotides. J. Clin. Invest. 106:2000;1071-1075.
6. Morishita R., Gibbons G.H., Horiuchi M., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA. 92:1995;5855-5859.
7. Tomita N., Horiuchi M., Tomita S., Gibbons G.H., Kim J.Y., Baran D., Dzau V.J. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro. Am. J. Physiol. 275:1998;F278-F284.
8. Ehsan A., Mann M.J., Dell'Acqua G., Dzau V.J. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J. Thorac. Cardiovasc. Surg. 121:2001;714-722.
9. Mann M.J., Whittemore A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., Orav E.J., Ehsan A., Dell'Acqua G., Dzau V.J. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 354:1999;1493-1498.
10. Yonemitsu Y., Kaneda Y., Morishita R.et al. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (Hemagglutinating Virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab. Invest. 75:1996;313-323.
11. Leyen H.V.L., Gibbons G.H., Morishita R.et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of ec-nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA. 92:1995;1137-1141.
12. Kawauchi M., Suzuki J., Morishita R.et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ. Res. 87:2000;1063-1068.
13. Morishita R., Gibbons G.H., Ellison K.E., Nakajima M., Leyen H.V.L., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest. 93:1994;1458-1464.
14. Morishita R., Gibbons G.H., Horiuchi M., Nakajima M., Ellison K.E., Lee W., Kaneda Y., Ogihara T., Dzau V.J. Molecular delivery system for antisense oligonucleotides: enhanced effectiveness of antisense oligonucleotides by HVJ-liposome mediated transfer. J. Cardiovasc. Pharmacol. Ther. 2:1996;213-222.
15. Feldman L.J., Tahlil O., Steg P.G. Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives. Semin. Interv. Cardiol. 1:1996;203-208.
16. Dzau V.J., Mann M.J., Morishita R.et al. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc. Natl. Acad. Sci. USA. 93:1996;11421-11425.
17. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 286:1999;2244-2245.
18. Bult H. Restenosis: a challenge for pharmacology. Trends Pharmacol. Sci. 21:2000;274-279.
19. Mehan V.K., Meier B. Conventional coronary angioplasty. Curr. Opin. Cardiol. 8:1993;645-651.
20. Tachibana K., Uchida T., Ogawa K.et al. Induction of cell-membrane porosity by ultrasound. Lancet. 353:1999;1409.
21. Huber P.E., Pfisterer P. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 7:2000;1516-1525.
22. Manome Y., Nakamura M., Ohno T.et al. Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo. Hum. Gene Ther. 11:2000;1521-1528.
23. Matsushita H., Morishita R., Aoki M.et al. Transfection of antisense p53 tumor suppressor gene oligodeoxynucleotides into rat carotid artery resulted in abnormal growth of vascular smooth muscle cells. Circulation. 101:2000;1447-1452.
24. Libby P., Schwartz D., Brogi E.et al. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 86:1992;III-47-III-52.
25. Chang M.W., Barr E., Seltzer J.et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
26. Morishita R., Gibbons G.H., Ellison K.E.et al. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA. 90:1993;8474-8478.
27. Tachibana K., Tachibana S. Albumin microbubble echo-contrast material as an enhancer for ultrasound accelerated thrombolysis. Circulation. 92:1995;1148-1150.
28. Podell S., Burrascano C., Gaal M.et al. Physical and biochemical stability of Optison, an injectable ultrasound contrast agent. Biotechnol. Appl. Biochem. 30:1999;213-223.